VivoSeq
Other

Maintenance Therapy

0

Pipeline Programs

35

Active Trials

10

Companies Involved

Maintenance Therapy is an early-stage landscape with 0 programs across 10 companies. The most active players are Bristol-Myers Squibb, Frontier Biotechnologies Inc., Novartis.

Pipeline Metrics

Competitive Density

44/100

Pipeline Velocity

34/100

Mech. Concentration

N/A

Completion Rate

80/100

Attrition Rate

8/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

103

clinical trials

Completed32 · 31%
Unknown status28 · 27%
Recruiting18 · 17%
Not yet recruiting11 · 11%
Active, not recruiting6 · 6%
Terminated5 · 5%
Other3 · 3%

Trial Activity

103 trials

Adebrelimab + Apatinib in SCLC Maintenance Therapy
Recruiting·TTang-Du Hospital·Phase 2·NCT06475209·60 enrolled
Page 1 of 7

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)